Phase II Clinical Trial of Durvalumab (MEDI4736) and Lurbinectedin in Patients With Relapsed Extensive Stage Small Cell Lung Cancer Previously Treated With Chemotherapy and Immunotherapy
Latest Information Update: 28 May 2025
At a glance
- Drugs Durvalumab (Primary) ; Lurbinectedin (Primary)
- Indications Small cell lung cancer
- Focus Therapeutic Use
Most Recent Events
- 22 May 2025 Planned End Date changed from 1 Nov 2026 to 19 Apr 2031.
- 22 May 2025 Planned primary completion date changed from 1 Nov 2025 to 19 May 2027.
- 30 Dec 2024 Planned number of patients changed from 106 to 46.